HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Rhea-AI Summary

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) announced that the NDA for sovleplenib in adult warm antibody autoimmune hemolytic anemia (wAIHA) was accepted for review by the NMPA with Priority Review and Breakthrough Therapy Designation.

The submission is supported by ESLIM-02 Phase II/III data: the Phase III part met its primary durable hemoglobin response endpoint in January 2026; Phase II published in The Lancet Haematology showed ORR 43.8% vs 0% at eight weeks and 66.7% over 24 weeks. ClinicalTrials.gov ID: NCT05535933.

Positive

• NDA accepted with Priority Review by NMPA for sovleplenib in wAIHA
• Breakthrough Therapy Designation granted by NMPA in March 2026
• Phase III met primary endpoint (durable hemoglobin response within weeks 5–24, Jan 2026)
• Phase II Lancet results: ORR 43.8% vs 0% at 8 weeks; 66.7% at 24 weeks

Negative

• Approval pending: regulatory review ongoing so market access and timing remain uncertain
• Small patient population: estimated prevalence ~17 per 100,000 adults, limiting addressable market size

News Market Reaction – HCM

-1.69%

-1.69% Session close to close

In the Apr 29 session, HCM declined 1.69%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on China’s NDA acceptance with priority review and Breakthrough Therapy De...

Analysis

This announcement centers on China’s NDA acceptance with priority review and Breakthrough Therapy Designation for sovleplenib in wAIHA, backed by Phase II/III ESLIM-02 data showing hemoglobin benefits and an overall response rate up to 66.7%. It follows earlier disclosures that the Phase III portion met its primary endpoint. Investors may watch upcoming EHA 2026 data, broader regulatory progress, and how this indication complements HUTCHMED’s existing hematology and oncology portfolio.

Key Figures

AIHA incidence: 0.8–3.0 per 100,000 adults per year AIHA prevalence: 17 per 100,000 adults AIHA death rate: 8–11% +3 more

6 metrics

AIHA incidence 0.8–3.0 per 100,000 adults per year Epidemiology of autoimmune hemolytic anemia

AIHA prevalence 17 per 100,000 adults Epidemiology of autoimmune hemolytic anemia

AIHA death rate 8–11% Mortality in autoimmune hemolytic anemia

wAIHA share of AIHA 75–80% Proportion of adult AIHA cases that are warm antibody type

ORR first 8 weeks 43.8% vs 0% Phase II ESLIM-02, sovleplenib vs placebo, first 8 weeks

ORR over 24 weeks 66.7% Phase II ESLIM-02, 24 weeks of sovleplenib treatment

Historical Context

5 past events · Latest: Apr 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 08	Clinical data preview	Positive	+1.2%	Announcement of new preclinical and clinical data for pipeline assets at AACR 2026.
Mar 22	Trial initiation	Positive	+0.4%	Start of registrational Phase III trial of HMPL-760 in relapsed/refractory lymphoma.
Mar 09	Product withdrawal	Negative	-0.6%	Worldwide withdrawal and recall of TAZVERIK after safety findings and halted trials.
Mar 06	Board changes	Neutral	+0.0%	Planned retirement of an independent director and reallocation of board committee roles.
Mar 05	Earnings and update	Positive	+1.5%	2025 results with net income, strong cash balance, and growth in key oncology sales.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news items, both positive and negative, have shown modest but consistently aligned price reactions.

Recent Company History

Over the past several months, HUTCHMED has reported multiple R&D and corporate milestones. A Mar 5, 2026 full-year 2025 update highlighted $548.5 million in revenue and a strong cash position, with a 1.5% positive reaction. Earlier, a Mar 22, 2026 Phase III trial initiation in lymphoma and an Apr 8, 2026 AACR data preview also drew small gains. A negative update on TAZVERIK on Mar 9, 2026 led to a slight decline. Today’s NDA acceptance for sovleplenib fits this pattern of clinically focused news with modest aligned moves.

Key Terms

new drug application, priority review, breakthrough therapy designation, spleen tyrosine kinase, +4 more

8 terms

new drug application regulatory

"the New Drug Application (“NDA”) for sovleplenib for the treatment"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

priority review regulatory

"has been accepted for review and granted priority review by the China"

Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.

breakthrough therapy designation regulatory

"granted Breakthrough Therapy Designation to sovleplenib for the treatment"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

spleen tyrosine kinase medical

"oral inhibitor targeting spleen tyrosine kinase (“Syk”), being developed"

A spleen tyrosine kinase (SYK) is a protein in immune and blood cells that acts like a biochemical switch, passing signals that control inflammation, cell survival and immune responses. Investors care because drugs that block or modify SYK can change disease outcomes in autoimmune disorders and certain blood cancers, so progress or setbacks in SYK-targeting therapies—trial results, approvals, safety issues—can strongly affect a company’s clinical and commercial prospects.

autoimmune hemolytic anemia medical

"Autoimmune hemolytic anemia (“AIHA”) is an autoimmune disorder"

Autoimmune hemolytic anemia is a condition where the immune system mistakenly destroys the body’s red blood cells, leading to fatigue, shortness of breath and low oxygen delivery—think of the body attacking its own delivery trucks. For investors, it matters because the condition drives demand for specific diagnostics, therapies and safety monitoring, can influence clinical-trial design and regulatory review, and may create commercial or liability risks for companies developing related drugs or devices.

warm antibody autoimmune hemolytic anemia medical

"for the treatment of adult patients with warm antibody autoimmune hemolytic anemia"

Warm antibody autoimmune hemolytic anemia is a condition in which the immune system mistakenly targets and destroys a person’s red blood cells at normal body temperature, causing fatigue, shortness of breath and low blood counts. For investors, it matters because it can drive demand for specific drugs and diagnostics, affect clinical trial outcomes and regulatory reviews, and create costs or liabilities for healthcare providers and biopharma companies—think of it as friendly fire that creates a market and risk landscape.

overall response rate medical

"demonstrated encouraging hemoglobin benefit compared with placebo, with overall response rate of 43.8%"

Overall response rate is the percentage of patients in a clinical study whose measurable disease shrinks or disappears after receiving a treatment. Investors watch it like a product’s “hit rate” because higher response rates can signal a drug’s effectiveness, boost chances of regulatory approval and market demand, and affect a company’s future revenue prospects, similar to how a higher batting average suggests a more reliable player.

double blind, placebo-controlled medical

"ESLIM-02, a randomized, double blind, placebo-controlled China Phase II/III study"

A double blind, placebo-controlled study is a clinical trial in which participants are randomly assigned to receive either the active treatment or an inactive substitute, and neither the participants nor the researchers know who got which until the study ends — like a blind taste test for a new medicine. Investors care because this design reduces bias and produces more reliable evidence on safety and effectiveness, which strongly affects regulatory approval, market potential, and the financial risk of the drug.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Administration (“NMPA”). Sovleplenib is a novel, selective, oral inhibitor targeting spleen tyrosine kinase (“Syk”), being developed for the treatment of immune diseases and hematological malignancies.

Autoimmune hemolytic anemia (“AIHA”) is an autoimmune disorder characterized by the destruction of red blood cells (“RBCs”) due to the production of antibodies against RBC. The incidence of AIHA is estimated to be 0.8-3.0/100,000 adults per year with an estimated prevalence of 17 per 100,000 adults and a death rate of 8-11%.^1,2 wAIHA is the most common form of AIHA,³ accounting for about 75-80% of all adult AIHA cases.⁴

The NDA is supported by data from ESLIM-02, a randomized, double blind, placebo-controlled China Phase II/III study in adult patients with primary or secondary wAIHA who had relapsed or were refractory to at least one prior line of standard treatment. In January 2026, the Phase III part of the trial met its primary endpoint of durable hemoglobin (Hb) response rate within weeks 5 to 24 of treatment. The Phase III results will be presented at the upcoming European Hematology Association (EHA) Congress 2026.

Results from the Phase II part of the study published in The Lancet Haematology in January 2025 demonstrated encouraging hemoglobin benefit compared with placebo, with overall response rate of 43.8% vs 0% in the first 8 weeks, and overall response rate of 66.7% during the 24 weeks of sovleplenib treatment (including patients that crossed over from placebo) with a favorable safety profile.⁵ Additional details of the study may be found at clinicaltrials.gov, using identifier NCT05535933.

Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said, “We are pleased to have submitted the NDA for sovleplenib in wAIHA, securing both Priority Review and Breakthrough Therapy Designation from the NMPA. This marks the second indication for which we have submitted an NDA for sovleplenib and underscores its broad potential as a novel oral Syk inhibitor. We look forward to providing this much-needed option for wAIHA patients with few treatment alternatives, while strengthening our hematology portfolio with this valuable new indication.”

The NMPA granted Breakthrough Therapy Designation to sovleplenib for the treatment of wAIHA in March 2026, as a potential new treatment for a serious condition for which there are no effective treatment options, and where clinical evidence demonstrates significant advantages over existing therapies.

About Sovleplenib and wAIHA

Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.

The accelerated clearance of antibody-coated RBCs by immunoglobulin Fc-gamma receptor (FcγR) bearing macrophages is thought to be the pathogenic mechanism in wAIHA.⁶ Activated Syk mediates downstream signaling of the activated Fc receptors in phagocytic cells, resulting in phagocytosis of RBCs.⁷ In addition, activation of Syk through the B-cell receptor mediates activation and differentiation of B-lymphocytes into antibody secreting plasma cells.⁸ Inhibition of Syk may have potential effects in the treatment of wAIHA through inhibition of phagocytosis and reduction of antibody production.

In addition to wAIHA, sovleplenib is also being studied in immune thrombocytopenia (“ITP”). Positive results from ESLIM-01 (NCT05029635), a Phase III trial in China of sovleplenib in patients with primary ITP, have been published in The Lancet Haematology. The NMPA accepted for review the resubmitted NDA filing for the treatment of ITP and granted it priority review in February 2026. According to IQVIA, China has 430,000 existing patients with 41,000 new ITP patients each year. About half of ITP patients fail to have satisfactory results from currently approved treatments such as TPO (thrombopoietin) /TPO-RAs (thrombopoietin receptor agonists).

HUTCHMED currently retains all rights to sovleplenib worldwide.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the review of a NDA for sovleplenib for the treatment of wAIHA with the NMPA and the timing of such review, therapeutic potential of sovleplenib for the treatment of wAIHA and the further development of sovleplenib in this and other indications. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the timing and outcome of clinical studies and the sufficiency of clinical data to support NDA approval of sovleplenib for the treatment of wAIHA or other indications in China or other jurisdictions, its potential to gain approvals from regulatory authorities on an expedited basis or at all, the efficacy and safety profile of sovleplenib, HUTCHMED’s ability to fund, implement and complete its further clinical development and commercialization plans for sovleplenib and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith	+44 20 7260 1000

^{_______________________________________
1} Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007; 29 (1):1-9. doi: 10.1016/j.jaut.2007.05.002.
² Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients. Am J Hematol. 2014; 89 (9):E150-5. doi: 10.1002/ajh.23767.
³ Cotran Ramzi S, Kumar Vinay, Fausto Nelson, Nelso Fausto, Robbins Stanley L, Abbas Abul K. Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders; 2005. p. 637.
⁴ Gehrs BC, Friedberg RC. Autoimmune haemolytic anemia. Am J Hematol. 2002; 69:258–271. doi: 10.1002/ajh.10062.
⁵ Zhao X, Sun J, Zhang Z, et al. Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study. Lancet Haematol. 2025;12(2):e97-e108. doi:10.1016/S2352-3026(24)00344-2
⁶ Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev. 2010; 24(3):195‐210. doi: 10.1016/j.tmrv.2010.03.002.
⁷ Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018; 14(10):857‐872. doi: 10.1080/1744666x.2018.1521722.
⁸ Davidzohn N, Biram A, Stoler‐Barak L, Grenov A, Dassa B, Shulman Z. SYK degradation restrains plasma cell formation and promotes zonal transitions in germinal centers. J Exp Med. 2020; 217(3):e20191043. doi: 10.1084/jem.20191043.

FAQ

What did HUTCHMED (HCM) announce about sovleplenib on April 29, 2026?

HUTCHMED announced NDA acceptance with Priority Review and Breakthrough Therapy Designation for sovleplenib in wAIHA. According to the company, the submission is supported by ESLIM-02 Phase II/III data including a Phase III primary endpoint met in January 2026.

What Phase III result supports HCM's NDA for sovleplenib in wAIHA?

The Phase III part of ESLIM-02 met its primary durable hemoglobin response endpoint within weeks 5–24. According to the company, this occurred in January 2026 and underpins the NDA filing.

What were the key Phase II efficacy numbers for sovleplenib reported by HCM?

Phase II published in The Lancet Haematology showed ORR 43.8% versus 0% at eight weeks and 66.7% over 24 weeks. According to the company, safety was reported as favorable in that study.

What does NMPA Breakthrough Therapy Designation mean for HCM's sovleplenib approval timeline?

Breakthrough designation can expedite development and review timelines but does not guarantee approval. According to the company, the NMPA granted that designation in March 2026 to prioritize review.

How large is the patient population for wAIHA relevant to HCM's sovleplenib opportunity?

wAIHA represents about 75–80% of adult AIHA, with an estimated prevalence of 17 per 100,000 adults. According to the company, AIHA incidence is 0.8–3.0 per 100,000 annually, indicating a rare-disease population.